1. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). (February 2023) Authors: Chen, Inna M.; Donia, Marco; Chamberlain, Christopher A.; Jensen, Agnete W.P.; Draghi, Arianna; Theile, Susann; Madsen, Kasper; Hasselby, Jane P.; Toxværd, Anders; Høgdall, Estrid; Lorentzen, Torben; Wilken, Eva E.; Geertsen, Poul; Svane, Inge M.; Johansen, Julia S.; Nielsen, Dorte Journal: European journal of cancer Issue: Volume 180(2023) Page Start: 125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization. Issue 2 (August 2018) Authors: Kronborg, Camilla; Serup-Hansen, Eva; Lefevre, Anna; Wilken, Eva E.; Petersen, Jørgen B.; Hansen, Jolanta; Schouboe, Annette; Nyvang, Lars; Spindler, Karen-Lise G. Journal: Radiotherapy and oncology Issue: Volume 128:Issue 2(2018) Page Start: 375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗